Hyaluronidase zzxf
Estrogen Receptor-positive Breast Cancer
Dana-Farber Cancer Instituteprotein_peptidePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
76 Active assets in the Estrogen Receptor-positive Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN Dana-Farber Cancer Institute | Phase 4 | BBB |
EXEMESTANE National Cancer Institute (NCI) | Phase 4 | BBB |
Everolimus UNC Lineberger Comprehensive Cancer Center | Phase 4 | BBB |
TAMOXIFEN Dana-Farber Cancer Institute | Phase 4 | BB |
Abemaciclib Jonsson Comprehensive Cancer Center | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Hyaluronidase zzxf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →